Pfizer (PFE) Earnings Date & Reports

Key Takeaways

• Pfizer is scheduled to report third-quarter 2026 results before the market opens on Tuesday, November 3, 2026.
• Consensus adjusted earnings per share (EPS, or profit per share after one-time items) sits near $0.77, below the $0.87 Pfizer posted in the third quarter of 2025.
• Full-year 2026 guidance calls for revenue of $60.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.
• The third quarter is expected to absorb an approximately $0.10 headwind tied to a $650 million acquired in-process research and development (IPR&D) charge from the Innovent Biologics licensing deal.
• Investors will focus on whether growth from newly launched and acquired drugs can continue offsetting steep declines in Pfizer's COVID-19 products.

Earnings Context and Why It Matters

Pfizer's third-quarter report lands at a pivotal moment for the drugmaker. The company is navigating a transition away from COVID-19 revenue while leaning on newer oncology and specialty products to drive growth, all against the backdrop of an approaching patent cliff on several legacy medicines. In the second quarter of 2026, Pfizer beat expectations with $15.03 billion in revenue and adjusted EPS of $0.77, and it raised the midpoint of its full-year revenue guidance. That performance reinforced confidence in its pipeline, but it also trimmed its COVID-19 product outlook to roughly $4 billion for the year. The upcoming report will test whether that momentum can be sustained.

Earnings Expectations

Wall Street consensus points to adjusted EPS near $0.77 for the third quarter of 2026, with estimates clustered in a range from roughly $0.76 to $0.79 depending on the source. That compares with adjusted EPS of $0.87 in the year-ago quarter, reflecting the continued unwind of COVID-19 product sales and the impact of the Innovent Biologics IPR&D charge.

For the full year, management has guided to revenue of $60.5 billion to $62.5 billion, a range raised by $500 million at the midpoint in August, and has reaffirmed adjusted diluted EPS of $2.80 to $3.00. Investors will watch several metrics closely: the growth rate of launched and acquired products (up 18% operationally in the second quarter), the pace of decline in Comirnaty and Paxlovid, and progress on the company's cost-reduction initiatives, including the additional $2.5 billion in productivity savings targeted for 2027 through 2029.

AI Screener

For investors looking to put earnings events like this into a broader market context, Tickeron's AI Screener offers an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to support your own research process.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter print is cautiously constructive. Pfizer shares have drifted higher since the August report, and the stock has shown positive post-earnings drift following its second-quarter release. In that quarter, a beat driven by oncology drugs such as Padcev and Lorbrena was tempered by a full-year sales outlook that still fell short of some analyst expectations, underscoring how sensitive the stock remains to guidance.

Key risk factors for the upcoming report include the trajectory of COVID-19 product revenue, foreign-exchange movements, potential tariff and pricing policy pressures in the U.S., and any commentary on the timing of patent expirations. Analysts will also be listening for updates on the Innovent Biologics partnership and whether non-COVID growth remains broad-based enough to offset legacy declines.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should track whether Pfizer's newer and acquired products sustain their double-digit operational growth. In the second quarter, this group grew 18% operationally, and management has signaled confidence that this momentum can continue. Sustained strength here is central to Pfizer's strategy of replacing lost COVID-19 revenue with diversified, longer-duration growth.

Cost discipline is another important theme. Pfizer has reaffirmed its full-year adjusted EPS range while absorbing the Innovent charge, and it has outlined additional productivity savings of $2.5 billion expected from 2027 through 2029. Commentary on how these savings are tracking, along with any updates to research and development spending plans, will help investors gauge margin trajectory.

Finally, watch for guidance nuances rather than just the quarterly figures. Because Pfizer raised its revenue midpoint but trimmed its COVID-19 outlook in August, the market will be looking for confirmation that the underlying non-COVID business remains on track. Any revision to the full-year revenue or adjusted EPS ranges, and any update on the patent cliff timeline, could move the stock more than the quarterly beat or miss itself.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations